Molecular testing is increasingly being utilized in oncology practice. Practitioners need to know the types of genetic alterations that can be detected, the technologies that can be used to detect these alterations, and the limitations of those techniques in order to ensure that their patients can be appropriately diagnosed, monitored, and matched with targeted therapies or recommended for clinical trials. 
Educating hematologists and oncologists about these recent advances would help them to use the response criteria and interpret complex clinical trial data more accurately in an era increasingly focused on targeted treatments with prolonged duration of therapy.

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement.

Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin’s lymphoma (NHL) characterized by multiple recurrences requiring retreatment.

Because of the therapeutic advances and clinical research affecting the management of hematologic malignancies, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers.  This peer interaction is an integral part in enhancing

The development of new and innovative cancer treatments has expanded the options available to manage patients with cancer.  However, with these advances come challenges for healthcare providers and patients.

This information was originally presented at the NCCN 12th Annual Congress: Hematologic Malignancies™ held in San Francisco, California, on October 6-7, 2017.

Pages

Subscribe to RSS - Lymphoma